Atara Biotherapeutics Class Action Lawsuit
Analysis based on 27 articles · First reported Apr 02, 2026 · Last updated Apr 19, 2026
The class action lawsuit against Atara Biotherapeutics, coupled with multiple rejections and a clinical hold from the United States — Food and Drug Administration for its lead product candidate tabelecleucel, has severely impacted Atara Biotherapeutics' stock price, leading to significant investor losses. This event highlights the substantial regulatory risks and potential for investor litigation in the biotechnology sector, particularly concerning drug development and approval processes.
Pomerantz LLP has filed a class action lawsuit against Atara Biotherapeutics and certain officers, alleging that the company made materially false and misleading statements regarding its business and prospects. The lawsuit covers the period from May 20, 2024, to January 9, 2026. The core of the complaint revolves around Atara Biotherapeutics' lead product candidate, tabelecleucel, and its regulatory journey. Atara Biotherapeutics submitted a Biologics License Application (BLA) to the United States — Food and Drug Administration in May 2024. However, the United States — Food and Drug Administration subsequently issued two Complete Response Letters (CRL) in January 2025 and January 2026, citing manufacturing issues and deficiencies in the supporting ALLELE study. Additionally, the United States — Food and Drug Administration placed a clinical hold on Atara Biotherapeutics' Investigational New Drug applications due to good manufacturing practice compliance issues. These regulatory setbacks led to substantial declines in Atara Biotherapeutics' stock price, with drops of 40.5%, 7.91%, and 56.99% following the respective announcements.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard